Lipid Metabolism — MCQs

Lipid Metabolism Indian Medical PG Practice Questions and MCQs

Question 371: Which lipoprotein is primarily associated with carrying cholesterol from peripheral tissues back to the liver?

A. HDL (Correct Answer)
B. LDL
C. VLDL
D. IDL

Explanation: ### Explanation **Correct Answer: A. HDL (High-Density Lipoprotein)** The correct answer is **HDL** because it is the primary mediator of **Reverse Cholesterol Transport (RCT)**. HDL picks up excess cholesterol from peripheral tissues and vascular endothelium (using the ABCA1 transporter) and transports it back to the liver for excretion in bile or conversion into bile acids. This process is cardioprotective, which is why HDL is colloquially known as "Good Cholesterol." **Analysis of Incorrect Options:** * **B. LDL (Low-Density Lipoprotein):** Known as "Bad Cholesterol," its primary role is the opposite of HDL. It transports cholesterol **from the liver to peripheral tissues**. High levels are strongly associated with atherosclerosis. * **C. VLDL (Very-Low-Density Lipoprotein):** Produced by the liver, its main function is to transport **endogenous triglycerides** to peripheral tissues (muscles and adipose tissue). * **D. IDL (Intermediate-Density Lipoprotein):** Formed during the degradation of VLDL. It serves as a precursor to LDL and is not involved in reverse transport. **NEET-PG High-Yield Pearls:** * **LCAT (Lecithin-Cholesterol Acyltransferase):** An enzyme activated by **Apo A-I** (found on HDL) that esterifies cholesterol within HDL, allowing it to be packed into the core of the lipoprotein. * **CETP (Cholesteryl Ester Transfer Protein):** Facilitates the exchange of cholesteryl esters from HDL for triglycerides from VLDL/LDL. * **Tangier Disease:** A rare genetic disorder caused by a mutation in the **ABCA1 transporter**, leading to extremely low HDL levels and orange-colored tonsils. * **Apo B-100** is the characteristic apolipoprotein for VLDL, IDL, and LDL, while **Apo A-I** is the hallmark of HDL.

Question 372: If a person has Total Cholesterol = 300 mg/dL, HDL = 25 mg/dL, and Triglycerides = 150 mg/dL, calculate the value of LDL.

A. 245 mg/dL (Correct Answer)
B. 125 mg/dL
C. 95 mg/dL
D. 55 mg/dL

Explanation: ### Explanation The calculation of LDL cholesterol is a high-yield topic for NEET-PG, primarily utilizing the **Friedewald Formula**. #### 1. Why Option A is Correct To find the LDL (Low-Density Lipoprotein) value, we use the Friedewald Equation: **LDL = Total Cholesterol – HDL – (Triglycerides / 5)** *Note: (Triglycerides / 5) is used to estimate VLDL cholesterol.* **Calculation:** * Total Cholesterol = 300 mg/dL * HDL = 25 mg/dL * VLDL = TG / 5 = 150 / 5 = 30 mg/dL * **LDL = 300 – 25 – 30 = 245 mg/dL** #### 2. Why Other Options are Incorrect * **Option B (125 mg/dL):** This result occurs if one incorrectly subtracts both HDL and TG directly from Total Cholesterol (300 - 25 - 150) without dividing TG by 5. * **Option C (95 mg/dL):** This is a distractor value that does not correlate with standard calculation errors in this formula. * **Option D (55 mg/dL):** This represents the sum of HDL and VLDL (25 + 30), rather than the LDL value itself. #### 3. Clinical Pearls & High-Yield Facts * **Limitation of Friedewald Formula:** It becomes **inaccurate** if Triglycerides are **>400 mg/dL**. In such cases, LDL must be measured directly. * **Non-HDL Cholesterol:** Calculated as (Total Cholesterol – HDL). It is increasingly used as a better predictor of cardiovascular risk than LDL alone. * **Target Levels:** For a healthy individual, LDL should ideally be <100 mg/dL. A value of 245 mg/dL indicates severe hypercholesterolemia, often seen in Familial Hypercholesterolemia (Type IIa). * **Sample Requirement:** For accurate TG and LDL calculation, a **12-14 hour fasting** sample is mandatory to clear chylomicrons from the blood.

Question 373: Tangier disease is due to deficiency of which type of lipoprotein?

A. LDL
B. HDL (Correct Answer)
C. VLDL
D. Chylomicrons

Explanation: **Explanation:** **Tangier Disease** is a rare autosomal recessive disorder characterized by a severe deficiency or near-absence of **High-Density Lipoprotein (HDL)** in the plasma. **Why HDL is the correct answer:** The underlying molecular defect is a mutation in the **ABCA1 (ATP-Binding Cassette transporter A1) gene**. Normally, the ABCA1 transporter facilitates the efflux of free cholesterol and phospholipids from peripheral cells (like macrophages) to apoA-I to form nascent HDL. In Tangier disease, this cholesterol transfer fails; consequently, apoA-I is rapidly cleared by the kidneys, leading to extremely low circulating HDL levels and the accumulation of cholesteryl esters in reticuloendothelial tissues. **Why other options are incorrect:** * **LDL:** Deficiencies in LDL or its precursor (Apo-B) are seen in *Abetalipoproteinemia*, not Tangier disease. * **VLDL & Chylomicrons:** These are triglyceride-rich lipoproteins. Their deficiency is associated with *Abetalipoproteinemia* (due to MTP gene mutations) or *Chylomicron Retention Disease*. In Tangier disease, VLDL levels may actually be normal or slightly decreased, but they are not the primary deficiency. **High-Yield Clinical Pearls for NEET-PG:** * **Pathognomonic Sign:** Large, **orange-colored tonsils** (due to cholesterol ester deposition in macrophages). * **Clinical Features:** Hepatosplenomegaly, lymphadenopathy, and peripheral neuropathy. * **Biochemical Profile:** Extremely low HDL (<5 mg/dL), low total cholesterol, and mild hypertriglyceridemia. * **Risk:** Despite low HDL, the risk of premature coronary artery disease is variable but generally increased.

Question 374: Fatty acid elongation occurs in which part of the cell?

A. Cytosol
B. Mitochondria (Correct Answer)
C. Lysosome
D. Nucleus

Explanation: **Explanation:** The synthesis of fatty acids occurs via two distinct processes: *de novo* synthesis and elongation. While *de novo* synthesis (up to Palmitate, C16) occurs in the cytosol, the further lengthening of these chains (elongation) occurs primarily in the **Mitochondria** and the **Endoplasmic Reticulum (Microsomal system)**. 1. **Why Mitochondria is Correct:** The mitochondrial system for fatty acid elongation involves the addition of acetyl-CoA units to existing fatty acid chains. It essentially operates as a reversal of $\beta$-oxidation, with the exception that NADPH is used as the reductant instead of FADH₂ in the final step. This system is highly active in the heart and brain. 2. **Why other options are incorrect:** * **Cytosol:** This is the site for *de novo* fatty acid synthesis (catalyzed by the Fatty Acid Synthase complex). It produces Palmitate (C16) but is not the site for subsequent elongation. * **Lysosome:** These are "suicide bags" involved in the degradation of macromolecules via acid hydrolases; they play no role in fatty acid synthesis or elongation. * **Nucleus:** This organelle houses genetic material and is involved in transcription/replication, not lipid metabolism. **High-Yield Clinical Pearls for NEET-PG:** * **Microsomal System:** The Endoplasmic Reticulum is the *other* major site of elongation, using Malonyl-CoA and NADPH. * **Rate-limiting step of Synthesis:** Acetyl-CoA Carboxylase (converts Acetyl-CoA to Malonyl-CoA). * **Essential Fatty Acids:** Humans lack the enzymes (desaturases) to introduce double bonds beyond carbon 9, which is why Linoleic and Linolenic acids must be obtained from the diet. * **Reducing Equivalent:** NADPH is the universal electron donor for fatty acid synthesis/elongation, primarily sourced from the HMP Shunt.

Question 375: All of the following statements about Lipoprotein Lipase are true, except:

A. Found in adipose tissue
B. Found in myocytes
C. Deficiency leads to hypertriglyceridemia
D. Does not require apoC-II as cofactor (Correct Answer)

Explanation: **Explanation:** **Lipoprotein Lipase (LPL)** is a key enzyme in lipid metabolism responsible for the hydrolysis of triglycerides (TAGs) found in Chylomicrons and Very Low-Density Lipoproteins (VLDL) into free fatty acids and glycerol. **Why Option D is the correct answer:** LPL is an **apoC-II dependent enzyme**. ApoC-II, which is donated by HDL to chylomicrons and VLDL, acts as an obligatory cofactor that activates LPL. Without apoC-II, LPL remains inactive, preventing the clearance of triglycerides from the blood. Therefore, the statement that it "does not require apoC-II" is false. **Analysis of other options:** * **Options A & B:** LPL is synthesized and secreted by **adipocytes** (adipose tissue) and **myocytes** (cardiac and skeletal muscle). It is then anchored to the luminal surface of capillary endothelial cells by heparan sulfate proteoglycans to interact with circulating lipoproteins. * **Option C:** Since LPL is the primary enzyme for clearing triglyceride-rich lipoproteins, its deficiency (or deficiency of its cofactor apoC-II) leads to **Type I Hyperlipoproteinemia (Familial Chylomicronemia Syndrome)**, characterized by severe hypertriglyceridemia and eruptive xanthomas. **High-Yield Clinical Pearls for NEET-PG:** * **Insulin Effect:** Insulin stimulates the synthesis and secretion of LPL in adipose tissue (promoting fat storage) but inhibits it in muscle. * **Heparin Release:** Intravenous heparin releases LPL from the endothelial wall into the plasma, a property used to measure "post-heparin lipolytic activity." * **Comparison:** Do not confuse LPL with **Hormone Sensitive Lipase (HSL)**; HSL acts *inside* adipocytes to mobilize stored fat during fasting and is inhibited by insulin.

Question 376: How many ATPs are formed from the complete beta-oxidation of stearic acid?

A. 7
B. 18
C. 56
D. 147 (Correct Answer)

Explanation: ### Explanation **1. Why the Correct Answer (D) is Right:** Stearic acid is a saturated fatty acid with **18 carbon atoms**. The calculation for ATP yield follows these steps: * **Beta-oxidation Cycles:** The number of cycles is $(n/2) - 1$. For 18 carbons, there are **8 cycles**. * **Products per Cycle:** Each cycle produces 1 FADH₂ (1.5 ATP) and 1 NADH (2.5 ATP). * $8 \text{ cycles} \times 4 \text{ ATP} = \mathbf{32 \text{ ATP}}$. * **Acetyl CoA Production:** The number of Acetyl CoA units is $n/2$. For 18 carbons, **9 Acetyl CoA** are produced. * **TCA Cycle Yield:** Each Acetyl CoA entering the TCA cycle yields 10 ATP. * $9 \text{ Acetyl CoA} \times 10 \text{ ATP} = \mathbf{90 \text{ ATP}}$. * **Gross Total:** $32 + 90 = 122 \text{ ATP}$. * **Activation Cost:** 2 ATP equivalents are consumed to convert Stearic acid to Stearyl-CoA. * **Net Yield:** $122 - 2 = \mathbf{120 \text{ ATP}}$. ***Note on NEET-PG Scoring:*** While modern biochemistry (Lehninger/Harper) calculates 120 ATP, many traditional medical exams still use the older conversion factors (1 FADH₂ = 2 ATP; 1 NADH = 3 ATP; 1 Acetyl CoA = 12 ATP). * *Old Calculation:* $(8 \times 5) + (9 \times 12) - 2 = 40 + 108 - 2 = \mathbf{146 \text{ or } 147 \text{ ATP}}$. Option D (147) is the classic "textbook" answer expected in this context. **2. Why Other Options are Wrong:** * **A (7):** This is the number of cycles for Palmitic acid (16C), not the ATP yield. * **B (18):** This represents the number of carbon atoms in Stearic acid. * **C (56):** This is an arbitrary number with no metabolic significance for stearate. **3. Clinical Pearls & High-Yield Facts:** * **Palmitic Acid (16C):** The most common fatty acid; yields **106 ATP** (modern) or **129 ATP** (old). * **Rate-limiting Step:** Catalyzed by **Carnitine Acyltransferase-I (CAT-I)**, which is inhibited by Malonyl-CoA. * **Sudden Infant Death Syndrome (SIDS):** Often linked to **MCAD deficiency** (Medium-chain acyl-CoA dehydrogenase), impairing beta-oxidation. * **Jamaican Vomiting Sickness:** Caused by Hypoglycin A (in unripe ackee fruit), which inhibits acyl-CoA dehydrogenase.

Question 377: Fatty acid synthesis takes place in which cellular compartment?

A. Cytosol (Correct Answer)
B. Mitochondria
C. Lysosome
D. Nucleus

Explanation: **Explanation:** **1. Why Cytosol is Correct:** De novo fatty acid synthesis (Lipogenesis) occurs primarily in the **cytosol**. This is because the key multi-enzyme complex required for this process, **Fatty Acid Synthase (FAS)**, is located exclusively in the cytosol. Additionally, the process requires **NADPH** as a reducing agent, which is abundantly supplied in the cytosol by the Pentose Phosphate Pathway (HMP Shunt). While the precursor Acetyl-CoA is produced in the mitochondria, it is transported to the cytosol via the **Citrate-Malate Shuttle** to initiate synthesis. **2. Why Other Options are Incorrect:** * **Mitochondria:** This is the primary site for **$\beta$-oxidation** (breakdown of fatty acids) and the TCA cycle. While some fatty acid elongation occurs here, the primary synthesis does not. * **Lysosome:** These are "suicide bags" containing hydrolytic enzymes for the degradation of macromolecules; they are not involved in synthetic pathways. * **Nucleus:** The nucleus houses genetic material and is responsible for replication and transcription, not lipid metabolism. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Rate-Limiting Enzyme:** Acetyl-CoA Carboxylase (ACC), which requires **Biotin** as a cofactor. * **Activator/Inhibitor:** ACC is allosterically activated by **Citrate** and inhibited by **Palmitoyl-CoA** (the end product). * **The Shuttle:** Acetyl-CoA cannot cross the inner mitochondrial membrane; it exits as **Citrate**. * **Key Product:** The primary end product of this pathway is **Palmitate** (a 16-carbon saturated fatty acid). * **Mnemonic:** "Synthesis in the City (Cytosol), Breakdown in the Mill (Mitochondria)."

Question 378: Which oil contains the maximum proportion of unsaturated fatty acids?

A. Mustard oil
B. Groundnut oil
C. Safflower oil (Correct Answer)
D. Coconut oil

Explanation: ### Educational Explanation The degree of unsaturation in dietary fats is determined by the number of double bonds in their fatty acid chains. High intake of **Polyunsaturated Fatty Acids (PUFA)** is clinically significant as they help lower LDL cholesterol and reduce the risk of cardiovascular diseases. **Why Safflower Oil is Correct:** Safflower oil contains the highest concentration of unsaturated fatty acids (approximately **85–90%**), specifically **Linoleic acid** (an omega-6 PUFA). In medical biochemistry, it is often cited as the gold standard for high PUFA content, making it a preferred dietary recommendation for patients with hyperlipidemia. **Analysis of Incorrect Options:** * **Mustard Oil:** While it contains high levels of monounsaturated fatty acids (MUFA) like Oleic acid and Erucic acid, its total PUFA content is significantly lower than that of safflower oil. * **Groundnut (Peanut) Oil:** This is primarily a MUFA-rich oil (about 50% Oleic acid). While healthier than saturated fats, its total unsaturation level does not match safflower or sunflower oils. * **Coconut Oil:** This is a **saturated fat** (approx. 90% saturated). It is unique because it is rich in Medium-Chain Triglycerides (MCTs) like Lauric acid, but it has the *least* proportion of unsaturated fatty acids among the options. **High-Yield Clinical Pearls for NEET-PG:** * **P/S Ratio:** The ratio of Polyunsaturated to Saturated fatty acids. Safflower oil has one of the highest P/S ratios (~10:1). * **Essential Fatty Acids (EFA):** Linoleic acid (ω-6) and Linolenic acid (ω-3) cannot be synthesized by the body and must be obtained from oils like safflower and sunflower. * **Order of PUFA content:** Safflower > Sunflower > Corn > Soyabean > Groundnut. * **Coconut Oil Exception:** Despite being a plant oil, it is solid at room temperature due to its high saturated fat content, unlike most other vegetable oils.

Question 379: Acetyl-CoA is transported out of the mitochondria to serve as a substrate for fatty acid or cholesterol synthesis. Which of the following enzymes involved in this transport process provides NADPH required for these reductive biosynthesis reactions?

A. ATP-citrate lyase
B. Citrate synthase
C. Malate dehydrogenase
D. Malic enzyme (Correct Answer)

Explanation: **Explanation:** Fatty acid synthesis occurs in the cytosol, but Acetyl-CoA is produced in the mitochondria. Since the inner mitochondrial membrane is impermeable to Acetyl-CoA, it condenses with oxaloacetate to form **Citrate**, which is transported out via the tricarboxylate transporter (the **Citrate Shuttle**). **Why Malic Enzyme is correct:** Once in the cytosol, citrate is cleaved back into Acetyl-CoA and oxaloacetate. The oxaloacetate is reduced to malate, which is then decarboxylated by **Malic Enzyme** to form pyruvate. This specific reaction reduces NADP+ to **NADPH**. This is a high-yield concept because NADPH is the essential reducing equivalent required for the reductive biosynthesis of fatty acids and cholesterol. **Analysis of Incorrect Options:** * **A. ATP-citrate lyase:** This enzyme cleaves Citrate into Acetyl-CoA and Oxaloacetate in the cytosol. While it is essential for the shuttle, it does not produce NADPH. * **B. Citrate synthase:** This is a mitochondrial enzyme that condenses Acetyl-CoA and Oxaloacetate to form Citrate. It is the first step of the TCA cycle and the shuttle, but it does not generate reducing power. * **C. Malate dehydrogenase:** The cytosolic version of this enzyme converts oxaloacetate to malate using NADH. It actually *consumes* reducing equivalents rather than producing NADPH. **High-Yield NEET-PG Pearls:** * **Sources of NADPH:** The two primary sources for fatty acid synthesis are the **Pentose Phosphate Pathway (HMP Shunt)** (major source) and the **Malic Enzyme** reaction (minor but significant source). * **Rate-limiting step:** The rate-limiting enzyme for fatty acid synthesis is **Acetyl-CoA Carboxylase (ACC)**, which requires Biotin. * **Location:** Remember "Link reaction/TCA = Mitochondria" vs. "Fatty acid synthesis = Cytosol." The Citrate Shuttle bridges this gap.

Question 380: What is the best marker for the prediction of coronary artery disease?

A. LDL/HDL ratio (Correct Answer)
B. Serum cholesterol
C. Cholesterol/Triglyceride ratio
D. Blood cholesterol

Explanation: **Explanation:** The prediction of Coronary Artery Disease (CAD) depends not just on the absolute level of lipids, but on the balance between pro-atherogenic and anti-atherogenic lipoproteins. **Why LDL/HDL ratio is the correct answer:** The **LDL/HDL ratio** is considered the most potent predictor of cardiovascular risk because it reflects the clinical "tug-of-war" between cholesterol deposition and removal. * **LDL (Low-Density Lipoprotein):** Known as "bad cholesterol," it transports cholesterol from the liver to peripheral tissues, including coronary arteries, leading to plaque formation (atherogenesis). * **HDL (High-Density Lipoprotein):** Known as "good cholesterol," it mediates **Reverse Cholesterol Transport**, removing excess cholesterol from macrophages in the arterial wall and transporting it back to the liver. A high ratio indicates a significant imbalance favoring lipid deposition over clearance, making it a superior marker compared to individual lipid parameters. **Why other options are incorrect:** * **Serum Cholesterol / Blood Cholesterol (Options B & D):** Total cholesterol is a poor predictor because it includes HDL. A patient may have high total cholesterol due to high HDL (low risk) or high LDL (high risk); thus, it lacks specificity. * **Cholesterol/Triglyceride ratio (Option C):** While elevated triglycerides are a risk factor, this ratio is primarily used to differentiate types of hyperlipoproteinemias (e.g., Type III Dysbetalipoproteinemia) rather than as a primary screening tool for CAD risk. **High-Yield Clinical Pearls for NEET-PG:** * **Apo B/Apo A1 ratio:** Emerging as an even more accurate predictor than the LDL/HDL ratio in some studies (Apo B represents all atherogenic particles). * **Friedewald Formula:** Used to calculate LDL ($LDL = Total\ Cholesterol – HDL – [TG/5]$). This formula is invalid if Triglycerides are $>400\ mg/dL$. * **Statins:** The primary drug class used to lower the LDL/HDL ratio by inhibiting HMG-CoA reductase.

Practice by Chapter

Lipid Classification and Chemistry

Practice Questions

Fatty Acid Oxidation

Practice Questions

Ketone Body Metabolism

Practice Questions

Fatty Acid Synthesis

Practice Questions

Metabolism of Triacylglycerols

Practice Questions

Phospholipid Metabolism

Practice Questions

Cholesterol Metabolism and Biosynthesis

Practice Questions

Bile Acids and Bile Salts

Practice Questions

Lipoprotein Metabolism and Transport

Practice Questions

Dyslipidemias and Atherosclerosis

Practice Questions

Prostaglandins and Eicosanoids

Practice Questions

Fatty Liver and Lipotropic Factors

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free